Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
ELPROINTL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Elpro International Ltd has acquired 1,33,086 fresh equity shares of Cohance Lifesciences Limited for a cash consideration of INR 4.79 Crores, classified as an investment purpose acquisition. Post-acquisition, Elpro's total holding in Cohance rises to 2,48,813 shares from 1,15,727 shares previously. Cohance Lifesciences is a pharmaceutical company (CDMO, APIs, specialty chemicals, formulations) incorporated in 2018, with a consolidated FY25 turnover of ₹1,256.14 Crores and operations in India and the USA. The transaction is not a related party transaction, and no regulatory approvals are specified as required.
This is a relatively small investment (₹4.79 Cr) by Elpro in a much larger pharmaceutical entity, suggesting it is a portfolio/stake-building move rather than a control acquisition. For shareholders, the immediate financial impact is limited, but it signals Elpro's strategic interest in the pharma sector.